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Summary Survival analyses of patients with cancer of the cervix uteri, corpus uteri or ovary registered at
Cambridge in 1960-1979 show that, although the long-term survivors had mortality rates similar to those of a
normal age-matched population and might therefore be considered 'statistically cured', their risk of dying
from their original cancer was still much higher than normal. Death rates from other cancers were slightly
increased in cervix patients but not in corpus and ovary. At all three sites there was no evidence that deaths
from non-malignant causes were increased. Only in cancer of the ovary was survival significantly better for
patients registered in 1970-1979 than for patients registered in 1960-1969.
Several groups of female patients with genital cancer
followed up beyond 10 years have been shown to have
mortality rates approximating to those of a normal
population of the same age distribution (Easson & Russell,
1968; Bush, 1979; Hakulinen et al., 1981). This has usually
been demonstrated by plotting the survival curve of the
patients together with the expected survival curve for the
similar normal population on a log-linear graph and
observing parallelism between the curves at longer follow up.
Berkson et al. (1952) first adopted this procedure for a
group of stomach cancer patients, and in a subsequent
similar study of breast cancer (Berkson et al., 1957) they
suggested that the long-term survivors, when the curves
became parallel, were cured - 'at least statistically speaking'.
It has, however, been shown in patients with cancer of the
breast that although the mortality rate from all causes after
25 years may not be very different from that of a normal
population, the rate from breast cancer is still greatly
increased, being about 15 times higher than expected
(Brinkley & Haybittle, 1984). Thus, statistical cure is not
necessarily the same as clinical cure, which has been defined
as the complete elimination of the disease so that the patient
would not have a higher risk of eventually dying from cancer
at the original site than would persons of the same age and
sex in the general population (Haybittle, 1983). We have,
therefore, used the information available in the Cambridge
Cancer Registration Bureau to see what evidence there is for
clinical cure in patients suffering from cancer of either the
cervix uteri, the corpus uteri or the ovary.
1960-69 and those registered in 1970-79. The latter group
had a maximum follow up of 16 years.
The results are presented in a similar format for each site
separately and then followed by a general discussion.
Cervix uteri
All patients except those in Stage 0 were included. There
were 754 patients in 1960-69 and 788 in 1970-79.
Comparison of the two periods There was a significant
difference (P<0.001) between the age distributions of the
patients registered in the two periods (Figure 1). The
distribution for the earlier period peaked at 40-44 years,
while the maximum of the 1970-79 distribution was at 50-59
years. The latter group had a greater proportion of patients
under 30 and a smaller proportion between 35 and 49 years
old. This change is also shown in the overall figures for
England and Wales (Registrar General, 1967-75; OPCS,
1979-83).
The survival curves for the two periods up to 16 years are
shown in Figure 2a. Although the curve for 1970-79 lies
above that for 1960-69, a comparison, unstandardised for
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Methods
All patients registered with cancer at these three sites from
1960 to 1979 inclusive were included in the study. They had
a minimum follow up of 6 years and a maximum of 25
years. Expected deaths in a normal population were
calculated using age-specific death rates for England and
Wales adjusted by the East Anglian standardised mortality
ratios (Registrar General, 1965-1987). Survival curves were
obtained by the actuarial method with deaths grouped in
yearly intervals. For the period beyond 5 years, the ratios of
observed to expected deaths were calculated in successive
5-year periods to see if the ratios approached unity.
There had been continual development of treatment
techniques over the study period. A subsidiary investigation
was therefore made into any change in survival experience
by dividing the patients into two groups, those registered in
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Figure 1 Age distributions of patients registered with cancer of
the cervix uteri in 1960-69 (---) and 1970-79 ( ).
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Figure 2 Survival curves for patients with cancer of (a) cervix
uteri, (b) corpus uteri and (c) ovary registered in 1960-69
(-----) and 1970-79 ( ).
stage, shows that the difference is not statistically significant
(0.3>P>0.2). The proportion of stage I cases was in fact
higher in the more recent period (Table I).
Long-term survival Figure 3a shows the survival curve for
both groups combined and also the expected survival curve
of a normal population of the same age distribution.
Approximate parallelism is reached after 15 to 20 years. The
lower dashed curve in Figure 3a, which is parallel to the
normal population curve, is fitted by eye to the tail of the
observed survival curve and indicates a statistically cured
group of -45%. The first row of Table II gives the ratios of
observed to expected deaths from all causes together with
the 95% confidence limits. Between 10 and 20 years the
ratios are only just significantly greater than unity and a
higher value than unity for 21-25 years cannot be excluded.
The calculation for the last quinquennium is based on
comparatively few patients, 109 entering the 21st year and
only 26 entering the 25th year. However, after 10 years the
death rate in the patients is not greatly increased over that in
a normal population.
Nevertheless, the death rate from cancer of the cervix is
still very much greater than expected (2nd row of Table II).
No deaths from cancer of the cervix were recorded from 21
to 25 years but the wide confidence interval in this period
shows that a large ratio of observed to expected deaths
cannot be excluded.
Deaths from other malignant disease were increased
slightly over the expected number (3rd row of Table II).
Only in the 6-10 year period is the ratio of observed to
expected significantly greater than unity, but, if the whole
period 6-25 years is considered as one, the observed to
expected ratio is 1.61 with 95% confidence limits of 1.15 and
2.19, i.e. again significantly greater than unity.
Deaths from non-malignant disease (4th row of Table II)
were not significantly different from expected. The ratio for
the whole 6-25 year period was 1.06 with 95% confidence
limits of 0.82 and 1.35.
Corpus uteri
The numbers of patients registered in 1960-69 and 1970-79
were 657 and 865 respectively.
Table I Stage distributions (%) in 1960-69 and 1970-79
Stage
Site Period I II III IV Unstaged
Cervix uteri 1960-69 38.4 33.9 18.8 7.6 1.4
1970-79 45.3 30.5 16.3 5.8 2.0
Corpus uteri 1960-69 71.5 2.4 17.0 8.8 0.2
1970-79 75.0 5.4 11.6 6.9 1.0
Ovary 1960-69 29.4 6.5 27.3 15.6 21.1
1970-79 25.4 9.0 29.0 19.0 17.6
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Figure 3 Survival curves for patients registered in 1960-79
() with cancer of (a) cervix uteri, (b) corpus uteri and (c)
ovary compared with curves for normal age-matched populations
(-----). The lower dashed curves are parallel to the upper
normal population curves and fitted by eye to the tails of the
observed patient survival curves.
Comparison of the two periods The age distributions in the
two periods were not significantly different (0.1>P>0.05).
Both peaked at 55-64 years. The survival curves for the two
periods (Figure 2b) are very similar although the percentage
of patients in stages I and II were slightly higher in the later
period (Table I).
Long-term survival Figure 3b shows the survival curve for
the whole group of 1,522 patients together with the expected
survival curve for a normal population of the same age
distribution. Approximate parallelism occurs after about 12
years and, as indicated by the lower dashed curve, would
suggest a statistically cured group of -55%. The ratios of
observed to expected deaths in successive quinquennia are
given in Table III. For deaths from all causes, the ratio is
just significantly greater than unity from 11 to 15 years,
includes unity in its 95% confidence interval from 16 to 20
years, and is significantly less than unity from 21 to 25 years.
Again, the calculation for the last quinquennium is based on
comparatively small numbers; 111 entering the 21st year and
33 entering the 25th year.
The ratio of observed to expected deaths from cancer of
the corpus uteri (2nd row of Table III) is much greater than
unity in all the quinquennia except the last, and, as for
cervix, a high ratio in 21-25 years cannot be excluded.
The 3rd row of Table III shows that there was no
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Table II Ratio of observed (0) to expected (E) deaths with 95% confidence limits (CL) for patients
with cancer of the cervix uteri
Period (years) Whole period
Cause ofdeath 6-10 11-15 16-20 21-25 6-25
All causes O/E 2.93 1.46 1.54 0.54 2.03
CL 2.40-3.54 1.05-1.98 1.01-2.24 0.11-1.59 1.74-2.35
Ca. cervix O/E 110 39.4 27.8 0 69.0
CL 83-144 21.0-67.3 9.0-65.0 0-83.6 53.9-86.9
Other malignant O/E 1.81 1.65 1.42 0.74 1.61
CLk 1.09-2.83 0.88-2.82 0.57-2.91 0.02-4.12 1.15-2.19
Non-malignant O/E 1.33 0.75 1.20 0.49 1.06
CL 0.92-1.86 0.42-1.24 0.67-1.98 0.06-1.76 0.82-1.35
Table III Ratio of observed (0) to expected (E) deaths with 95% confidence limits (CL) for patients
with cancer of the corpus uteri
Period (years) Whole period
Cause of death 6-10 11-15 16-20 21-25 6-25
All causes O/E 1.92 1.34 1.09 0.41 1.45
CL 1.63-2.26 1.05-1.68 0.78-1.48 0.16-0.84 1.28-1.63
Ca. corpus O/E 121 56 31 0 79
CL 92-157 32-91 10-72 0-60 63-96
Other malignant O/E 0.90 1.26 1.00 1.11 1.04
CL 0.53-1.44 0.70-2.07 0.40-2.06 0.23-3.24 0.75-1.41
Non-malignant O/E 1.03 0.99 0.95 0.28 1.04
CL 1.04-1.64 0.72-1.34 0.63-1.37 0.08-0.71 0.88-1.22
significant difference between observed and expected deaths
from other malignant disease. The ratio of observed to
expected for the whole period 6-25 years was 1.04 with 95%
confidence limits of 0.75 and 1.41. Deaths from non-
malignant disease (4th row of Table III) were similar to the
expected numbers except in the last quinquennium where
there is a suggestion that they might have been reduced.
However, the ratio for the whole period 6-25 years was 1.04
with 95% confidence limits of 0.88 and 1.22.
Ovary
There were 1,474 patients in all, 617 in 1960-69 and 857 in
1970-79.
Comparison of the two periods There was no significant
difference between the age distributions for the two periods
(0.20>P>0.10). Their maxima were at 65-69 years.
The survival curves for the two periods (Figure 2c) were
significantly different (0.025>P>0.01). At 15 years, the
survival rates for the 1960-69 and 1970-79 patients were
14% and 19% respectively. An examination of the stage
distribution in the two periods showed no improvement with
time of the proportion of earlier stage cases, stages I and II
accounting for about one third of the cases in both periods
(Table I).
Long-term survival The survival curve for the whole group
(Figure 3c) achieves approximate parallelism with that of the
normal population after
- 13 years and is consistent with
there being a statistically cured group of 22%. The observed
to expected ratios for deaths from all causes in the first row
of Table IV are not significantly different from unity in the
last two quinquennia. Because of the overall poor survival,
98 patients entered the 16th year and only 37 entered the
21st year.
Again there is no evidence for clinical cure. The death rate
from cancer of the ovary was much higher than normal
throughout the follow up (2nd row ofTable IV).
Deaths from other malignant disease (3rd row of Table
III) were not significantly different from expected. The
observed to expected ratio for the whole period 6-25 years
was 0.96 with 95% confidence limits of 0.48 and 1.73.
Similarly for deaths from non-malignant disease (4th row of
Table IV) where the ratio for the whole period was 0.79 with
95% confidence limits of 0.53 and 1.13.
Table IV Ratio of observed (0) to expected (E) deaths with 95% confidence limits (CL) for patients
with cancer of the ovary
Period (years) Whole period
Cause ofdeath 6-10 11-15 16-20 21-25 6-25
All causes O/E 2.94 1.90 1.18 0.56 2.21
CL 2.31-3.70 1.27-2.75 0.54-2.25 0.07-2.03 1.78-2.66
Ca. ovary O/E 129 38 25 28 84
CL 98-167 17-71 5-73 0.7-155 66-106
Other malignant O/E 0.85 1.53 0.60 0 0.96
CL 0.28-2.0 0.50-3.6 0.02-3.3 0-5.9 0.48-1.73
Non-malignant O/E 0.54 1.25 0.93 0.35 0.79
CL 0.26-0.99 0.68-2.10 0.30-2.18 0.01-1.93 0.53-1.13SURVIVAL EXPERIENCE OF FEMALE GENITAL CANCER 325
Discussion
In cancer of the cervix and corpus uteri there has been no
marked improvement in survival between the two decades.
This disappointing observation is somewhat mitigated for
cancer of the cervix by the fact that the number of stage 0
in situ cases registered increased from 173 in 1960-69 to 663
in 1970-79. These patients have an extremely good prognosis
(OPCS, 1982). There was some evidence for an improved
survival in the 1970-79 group of patients with cancer of the
ovary, although the overall results were still poor. This
improvement could not be attributed to a higher proportion
of early stage cases, but, as with all retrospective
comparisons, one must be cautious about concluding that it
might be due to better treatment methods.
There was some evidence for statistical cure at all three
sites, the survival curves becoming approximately parallel to
those of an age-matched normal population and the ratio of
observed to expected deaths after 15 years being near to
unity. The percentages cured in this statistical sense were
45%, 55% and 22% for patients with cancer of the cervix
uteri, corpus uteri and ovary respectively.
A consistent finding for all three sites was that the risk of
dying from the original cancer remained considerably
increased throughout the period, so that there was no
evidence for clinical cure. It is very unlikely that this finding
could be due to errors in death certification. Such errors as
have been reported (Heasman & Lipworth, 1966; Waldron &
Vickerstaff, 1977) could not account for the observed to
expected ratios of about 30 found in this study. In the 16-20
year period, the expected deaths from the original cancer are
only a small fraction of those expected from all causes (0.01,
0.004 and 0.016 for cervix uteri, corpus uteri and ovary
respectively). The large increase of observed compared with
expected specific cancer deaths at longer follow up is there-
fore quite compatible with the ratio of observed to expected
deaths from all causes approaching unity.
Deaths from other malignant disease were increased
slightly in cervix patients, but not in corpus and ovary. At
all three sites there was no evidence that deaths from non-
malignant disease were increased.
The main conclusion of this study is, therefore, that,
although long-term survivors after treatment of cancers of
the cervix uteri, corpus uteri and ovary suffer mortality rates
approximating to those of a normal population, they still
have a much higher risk of dying from their original cancer.
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